| Course | DNRS 6521 Advanced Pharmacology (DNP level) |
|---|---|
| Week | Week 3 |
| Paper type | Pharmacogenomic memo |
| Length | About 610 words, 4 pages |
| Format | Memo, APA 7 citations |
| School | Walden University |
| Program | Doctor of Nursing Practice (DNP) |
| Updated | October 2026 |
Free sample paper for DNRS 6521 Week 3
Memorandum
To: Oncology advanced practice providers and infusion nurses
From: DNP student, Advanced Pharmacology
Date: Month Day, Year
Re: One in twelve of our patients may clear fluorouracil at half speed: genotype DPYD before cycle 1
What the Variant Does to the Enzyme
Fluorouracil, and capecitabine after its conversion to fluorouracil, is inactivated mainly by dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene; most of an administered dose is broken down by this enzyme in the liver. Some DPYD variants abolish enzyme function, such as DPYD*2A, a splice-site change that skips an exon and yields a nonfunctional protein, while others, such as c.2846A>T and the c.1129-5923C>G haplotype, reduce it. A person carrying one nonfunctional or reduced-function allele has less DPD activity than a person with two normal alleles (Amstutz et al., 2018), and a meta-analysis of individual patient data linked the reduced-function variants c.1679T>G and c.1236G>A/HapB3 to severe fluoropyrimidine toxicity (Meulendijks et al., 2015).
What That Means for Exposure
Less DPD activity means slower breakdown of fluorouracil, so more active drug circulates and it circulates longer after each dose. The standard dose, calculated for body surface area on the assumption of normal DPD activity, produces a higher exposure in a carrier. The toxicities are the familiar ones, neutropenia, mucositis, diarrhea, and hand-foot syndrome, but they arrive earlier and more severely, and in people with complete or near-complete deficiency they can be fatal. The CPIC guideline therefore translates genotype into an activity score and recommends a reduced starting dose, typically by half, for people with intermediate activity, with later doses titrated to tolerance, and advises avoiding fluoropyrimidines in people with no activity (Amstutz et al., 2018).
Where It Matters and Where It Does Not
It matters most in two situations. The first is any standard-dose systemic regimen containing fluorouracil or capecitabine, as used for colorectal, breast, gastric, and head and neck cancers, because the first cycle is where unexpected severe toxicity strikes. In a prospective study in which 1,103 patients were genotyped before treatment, 85 (8%) carried one of four DPYD variants; carriers given a reduced starting dose still had more severe toxicity than noncarriers, 39% versus 23%, but for DPYD*2A and c.1679T>G carriers the risk relative to noncarriers fell well below that seen in an earlier cohort dosed without genotyping (Henricks et al., 2018). The second is the patient whose genotype is unknown and who had severe toxicity in cycle 1; a result may explain it and guide whether to continue at a lower dose.
It matters little for topical fluorouracil used on the skin, where systemic exposure is small, and it does not apply to drugs that DPD does not metabolize.
What Testing Can and Cannot Establish
A genotype panel detects the specific variants it tests for, usually four, and a carrier result is actionable. A normal result is reassuring but not proof of normal DPD activity, because rarer variants outside the panel also reduce function; severe toxicity in a patient with a normal panel should still prompt dose review (Amstutz et al., 2018). Turnaround is the practical limit. If the result will take a week or more and treatment is planned sooner, the test has to be ordered at the first consultation, not on the day of the first infusion. A result that arrives after cycle 1 protects only later cycles.
One Consequence for Our Practice
Starting next month, DPYD genotyping will be ordered at the first oncology consultation for every patient for whom a systemic fluoropyrimidine is being considered, and the infusion order set will not release a first dose until the result is documented or the oncologist records a reason to proceed without it. Carriers will start at the reduced dose the CPIC guideline recommends for their activity score and be titrated from there (Amstutz et al., 2018; Henricks et al., 2018).
References
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clinical Pharmacology & Therapeutics, 103(2), 210-216. https://doi.org/10.1002/cpt.911
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W., . . . Schellens, J. H. M. (2018). DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis. The Lancet Oncology, 19(11), 1459-1467. https://doi.org/10.1016/S1470-2045(18)30686-7
Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., Kleibl, Z., Kleiblova, P., Schwab, M., Zanger, U. M., Palles, C., Tomlinson, I., Gross, E., van Kuilenburg, A. B. P., Punt, C. J. A., . . . Schellens, J. H. M. (2015). Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data. The Lancet Oncology, 16(16), 1639-1650. https://doi.org/10.1016/S1470-2045(15)00286-7
What the DNRS 6521 Week 3 instructions ask for
The third week commonly asks you to explain a gene and drug interaction for a professional audience, often in memo form. You describe what the variant does to the enzyme or transporter, how that changes drug exposure and outcomes, and what clinicians should do with the information. Expect a word limit, frequently two pages, and the usual memo header block. References still appear in APA 7, usually drawn from CPIC or similar guidelines and key primary studies. The prompt may ask whether you would recommend testing and under what conditions. Clear headings and short paragraphs are part of the grade. Some sections specify the audience, such as a pharmacy and therapeutics committee or a clinic team, and expect the memo to address them directly.
How this DNRS 6521 Week 3 example is built
Two pages, a subject line that states the consequence rather than the topic, and five short blocks. The first block explains what an enzyme variant does at the level of the protein, in three sentences, without a chapter's worth of background. The second block converts that into exposure, which is the move most memos skip: it says whether the variant leaves more or less active compound circulating and for how long. A third block names the two categories of clinical situation where the difference is likely to matter and the situations where it is not. A fourth block covers what testing can and cannot establish, including turnaround as a practical limit. The closing block states one documented consequence for practice.
Reading the DNRS 6521 Week 3 rubric
Memos are marked on usability, so register carries real weight and academic paragraphing costs points even when the science is correct. The largest single share follows the conversion from mechanism to exposure, and a memo naming a variant without saying what it leaves circulating has stopped one step short of its assignment. Graders also read the negative block closely, since candor about where the variation is irrelevant is the clearest evidence a writer understands its scope. Length overruns are penalized harder in memo assignments than in papers because concision is the constraint being assessed. Citation style still applies at doctoral level, and a memo without support reads as opinion however sound. Closing on awareness rather than on a decision leaves the final criterion unearned in most rubrics of this kind.
Common DNRS 6521 Week 3 mistakes, and how to avoid them
Memos lose credit when they read like an essay with a memo header pasted on. Use headings and short paragraphs, and finish with something a prescriber can do on Monday. Another frequent mistake is overstating the test: a normal result does not rule out severe toxicity, since other variants and nongenetic causes exist. Say what testing cannot do. Students also give dose reductions without naming the activity score or phenotype they apply to; tie each change to a category. Keep the genetics accurate but brief, because the reader needs the consequence more than the molecular detail. Make sure the guideline you cite is the current version. End with one clear action for the team rather than a list of possibilities.
Get a DNRS 6521 Week 3 example written to your instructions
Send the memo prompt, the audience it names and any length ceiling, and a two-page document written for that audience comes back to you. The first custom one is free and arrives inside 24 to 48 hours. Test results belonging to a patient or to yourself stay private and play no part in what gets written.
More DNRS 6521 papers and DNP samples
- DNRS 6521 Week 1: Discussion Post
- DNRS 6521 Week 2: Case Write-Up
- DNRS 6521 Week 4: Decision Case
- DNRS 6521 Week 5: Discussion Post
- DNRS 6521 Week 6: Interaction Analysis
- DNRS 6521 Week 7: Monitoring Plan
- DNRS 6521 Week 8: Prescribing Ethics Case
- DNRS 6521 Week 9: Formulary Review
- DNRS 6521 Week 10: Deprescribing Plan
- DNRS 6521 Week 11: QI Proposal
- NURS 6001 Week 3: Boolean search trail
- DNRS 6501 Week 3: Case Analysis
- NURS 6002 Week 3: Practice-grounded nursing philosophy
- NURS 6914 Week 3: Total pain case
DNRS 6521 Week 3 questions, answered
Does a doctoral pharmacology course really assign memos?
Professional-format assignments are common in DNP sequences, where the point is writing for colleagues rather than for an academic reader. Walden publishes no week list that would confirm the placement, so treat the third week as a plausible slot rather than a fixed one. The memo structure holds wherever a prompt asks for a short professional document.
How technical should the genetics content be?
Enough to make the exposure claim credible and no more. The example spends three sentences at the protein level and then leaves. Colleagues reading a memo want the consequence, and graders assessing a professional-format assignment are checking whether the writer could tell what the audience needed from what the writer found interesting.
Should the memo recommend testing?
Only where the reasoning supports it and the limits are stated alongside. The example closes on a documented consequence rather than a general recommendation. A memo that urges testing without coverage, interpretation and turnaround attached is making a claim the reader cannot act on, and rubrics tend to read that as incomplete rather than as bold.
Where can I find a free DNRS 6521 Week 3 sample paper?
The full DPYD memo is on this page, with its header, the five sections from enzyme to practice consequence, and margin notes on register and length.
What does a DPYD variant mean for capecitabine in DNRS 6521 Week 3?
Reduced enzyme activity slows breakdown, so exposure and the risk of severe toxicity rise. The memo follows the CPIC approach of lowering the starting dose by activity score.